The performance of companies tied to flagship drugs like Viagra presents a challenging investment scenario . While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the expiry in key markets has introduced considerable volatility. Investors are now assessing the impact of generic competition